<DOC>
	<DOCNO>NCT02133105</DOCNO>
	<brief_summary>Although inotropes favorable effect central hemodynamics patient heart failure , effect renal hemodynamics incompletely define . The purpose study evaluate efficacy 75 min intravenous infusion levosimendan compare 75 min infusion dobutamine renal hemodynamics function patient chronic heart failure sign cardiorenal syndrome . The investigator hypothesis patient treat levosimendan show great increase renal blood flow glomerular filtration rate ( GFR ) treat dobutamine .</brief_summary>
	<brief_title>Levosimendan Versus Dobutamine Renal Function Heart Failure</brief_title>
	<detailed_description />
	<mesh_term>Heart Failure</mesh_term>
	<mesh_term>Cardio-Renal Syndrome</mesh_term>
	<mesh_term>Simendan</mesh_term>
	<mesh_term>Dobutamine</mesh_term>
	<criteria>Written , sign date informed consent Male Female subject ≥18 year age Chronic congestive heart failure schedule right side cardiac catheterization Left ventricular ejection fraction ≤ 40 % determine echocardiography Elevation N TerminalproBNP ≥ 500 ng/L Cardiorenal syndrome ( 30ml/min ≤ estimate GFR ≤ 80 ml/min ( MDRD ) Acute heart failure , untreated Systolic blood pressure &lt; 80 mmHg Tachycardia 100 bpm Angina Canadian Cardiovascular Society ( CCS ) class III high Aortic stenosis Hypertrophic cardiomyopathy Restrictive cardiomyopathy The presence kidney disease diagnose heart failure Administration radiographic contrast &lt; 1 week Radiographic contrast allergy In Investigator 's opinion , patient clinically significant disease could adversely affect study participation</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Heart failure</keyword>
	<keyword>Renal failure</keyword>
	<keyword>Inotropic drug</keyword>
	<keyword>Levosimendan</keyword>
	<keyword>Dobutamine</keyword>
</DOC>